Kinnate Biopharma (KNTE) Stock Price, News & Analysis $2.19 -0.10 (-4.37%) (As of 10:37 AM ET) Add Compare Share Share Today's Range$2.18▼$2.2850-Day Range$1.07▼$2.5052-Week Range$1.04▼$8.17Volume88,565 shsAverage Volume546,395 shsMarket Capitalization$103.18 millionP/E RatioN/ADividend YieldN/APrice Target$14.60 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaSustainability Kinnate Biopharma MarketRank™ Stock AnalysisAnalyst RatingHold2.20 Rating ScoreUpside/Downside557.7% Upside$14.60 Price TargetShort InterestBearish5.38% of Float Sold ShortDividend StrengthN/ASustainability-0.81Upright™ Environmental ScoreNews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($2.50) to ($1.31) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.13 out of 5 starsMedical Sector394th out of 942 stocksPharmaceutical Preparations Industry155th out of 424 stocks 3.1 Analyst's Opinion Consensus RatingKinnate Biopharma has received a consensus rating of Hold. The company's average rating score is 2.20, and is based on 1 buy rating, 4 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $14.60, Kinnate Biopharma has a forecasted upside of 557.7% from its current price of $2.22.Amount of Analyst CoverageKinnate Biopharma has only been the subject of 3 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted5.38% of the float of Kinnate Biopharma has been sold short.Short Interest Ratio / Days to CoverKinnate Biopharma has a short interest ratio ("days to cover") of 0.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous month Previous Next 0.0 Dividend Strength Dividend YieldKinnate Biopharma does not currently pay a dividend.Dividend GrowthKinnate Biopharma does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreKinnate Biopharma has received a 74.24% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Preclinical research services for physical health" and "Clinical research services for cancer" products. See details.Environmental SustainabilityThe Environmental Impact score for Kinnate Biopharma is -0.81. Previous Next 1.1 News and Social Media Coverage Search Interest7 people have searched for KNTE on MarketBeat in the last 30 days. This is an increase of 600% compared to the previous 30 days.MarketBeat Follows2 people have added Kinnate Biopharma to their MarketBeat watchlist in the last 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Kinnate Biopharma insiders have not sold or bought any company stock.Percentage Held by Insiders41.70% of the stock of Kinnate Biopharma is held by insiders. A high percentage of insider ownership can be a sign of company health. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Kinnate Biopharma are expected to grow in the coming year, from ($2.50) to ($1.31) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Kinnate Biopharma is -0.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Kinnate Biopharma is -0.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioKinnate Biopharma has a P/B Ratio of 0.44. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Kinnate Biopharma Stock (NASDAQ:KNTE)Kinnate Biopharma Inc., a clinical-stage oncology company, focuses on the discovery and development of small molecule kinase inhibitors to treat genomically defined cancers in the United States. The company develops KIN-2787, a rapidly accelerated fibrosarcoma inhibitor for the treatment of patients with lung cancer, melanoma, and other solid tumors; KIN-3248 small-molecule kinase inhibitors that target cancer-associated alterations in fibroblast growth factor receptors FGFR2 and FGFR3 genes; and small molecule research programs, including Cyclin-Dependent Kinase 12(CDK12) inhibitor in its KIN004 program. The company was incorporated in 2018 and is headquartered in San Francisco, California. Kinnate Biopharma Inc. is a former subsidiary of Fount Therapeutics, LLC.Read More KNTE Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart KNTE Stock News HeadlinesDecember 3, 2023 | americanbankingnews.comKinnate Biopharma Inc. (NASDAQ:KNTE) Given Average Recommendation of "Hold" by BrokeragesNovember 24, 2023 | finance.yahoo.comKinnate Biopharma, Madrigal Pharma, and More Stocks See Action From Activist InvestorsDecember 11, 2023 | DTI Trader (Ad)New CBOE “special perk” helps traders target income every weekendYou might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange. November 15, 2023 | msn.comWhy is Cancer-Focused Kinnate Biopharma Stock Trading Higher Today?November 15, 2023 | finance.yahoo.comOrbiMed Advisors LLC Reduces Stake in Kinnate Biopharma IncNovember 9, 2023 | finance.yahoo.comKinnate Biopharma Inc. Reports Third Quarter 2023 Financial Results and Recent Corporate UpdatesOctober 4, 2023 | theglobeandmail.comInstrument Name Kinnate Biopharma Inc Instrument Symbol (KNTE-Q)October 3, 2023 | finance.yahoo.comKinnate Biopharma (KNTE) Falls 40% in a Month: Here's WhyDecember 11, 2023 | DTI Trader (Ad)New CBOE “special perk” helps traders target income every weekendYou might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange. September 20, 2023 | msn.comJefferies Maintains Kinnate Biopharma (KNTE) Buy RecommendationSeptember 19, 2023 | msn.comBay Area biotech company Kinnate to lay off 70% of workforceSeptember 19, 2023 | msn.comWedbush Downgrades Kinnate Biopharma (KNTE)September 19, 2023 | msn.comWhy Is Cancer Firm Kinnate Biopharma Stock Trading Lower Today?September 19, 2023 | msn.comPiper Sandler Downgrades Kinnate Biopharma (KNTE)September 19, 2023 | markets.businessinsider.comAnalysts Move To Sidelines For Cancer Player Kinnate Biopharma After RestructuringSeptember 18, 2023 | msn.comKinnate slashes workforce by 70%, shelves three drug programsSeptember 18, 2023 | finance.yahoo.comKinnate Biopharma Inc. Announces Pipeline Updates, Strategic Reprioritization and Workforce RestructuringAugust 15, 2023 | markets.businessinsider.comKinnate Biopharma (KNTE) Receives a Buy from H.C. WainwrightAugust 8, 2023 | finance.yahoo.comKinnate Biopharma Inc. Reports Second Quarter 2023 Financial Results and Recent Corporate UpdatesJuly 28, 2023 | seekingalpha.comKRBP Kiromic BioPharma, Inc.June 11, 2023 | msn.comKinnate Biopharma: Trading Below Cash ValueJune 8, 2023 | msn.comHC Wainwright & Co. Reiterates Kinnate Biopharma (KNTE) Buy RecommendationJune 8, 2023 | msn.com10 Analysts Have This to Say About Kinnate BiopharmaJune 8, 2023 | msn.comThe Latest Analyst Ratings for Kinnate BiopharmaJune 7, 2023 | markets.businessinsider.comStifel Nicolaus Keeps Their Hold Rating on Kinnate Biopharma (KNTE)May 30, 2023 | markets.businessinsider.comStifel Nicolaus Reaffirms Their Hold Rating on Kinnate Biopharma (KNTE)May 18, 2023 | markets.businessinsider.comKinnate Biopharma in Focus: Analyst's Adjusted Price Target and the Potential of KIN-3248See More Headlines Receive KNTE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Kinnate Biopharma and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/09/2023Today12/11/2023Fiscal Year End12/31/2023Next Earnings (Estimated)3/20/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:KNTE CUSIPN/A CIK1797768 Webwww.kinnate.com Phone858-299-4699FaxN/AEmployees84Year FoundedN/APrice Target and Rating Average Stock Price Target$14.60 High Stock Price Target$26.00 Low Stock Price Target$4.00 Potential Upside/Downside+537.6%Consensus RatingHold Rating Score (0-4)2.20 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($2.78) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-116,270,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-62.31% Return on Assets-54.72% Debt Debt-to-Equity RatioN/A Current Ratio10.80 Quick Ratio10.80 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$5.06 per share Price / Book0.45Miscellaneous Outstanding Shares47,113,000Free Float27,467,000Market Cap$107.89 million OptionableNot Optionable Beta1.34 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report Key ExecutivesMr. Nima Farzan M.B.A. (Age 47)President, CEO & Director Comp: $891.95kMs. Neha Krishnamohan (Age 36)CFO, Principal Accounting Officer and Executive VP of Corporate Development Comp: $548.95kMr. Mark A. Meltz (Age 49)COO, General Counsel, Treasurer & Secretary Comp: $671.86kDr. Richard Thomas Williams MBBS (Age 54)Ph.D., Chief Medical Officer Dr. Robert Kania Ph.D.Senior Vice President of ResearchKey CompetitorsAnnovis BioNYSE:ANVSSelecta BiosciencesNASDAQ:RNACGlycoMimeticsNASDAQ:GLYC2seventy bioNASDAQ:TSVTAssertioNASDAQ:ASRTView All CompetitorsInsiders & InstitutionsCitigroup Inc.Bought 419,795 shares on 12/6/2023Ownership: 0.893%Jacobs Levy Equity Management Inc.Bought 345,572 shares on 11/17/2023Ownership: 0.954%Rock Springs Capital Management LPSold 341,162 shares on 11/15/2023Ownership: 0.861%GSA Capital Partners LLPBought 133,948 shares on 11/15/2023Ownership: 0.795%Pale Fire Capital SEBought 46,492 shares on 11/14/2023Ownership: 0.149%View All Insider TransactionsView All Institutional Transactions KNTE Stock Analysis - Frequently Asked Questions Should I buy or sell Kinnate Biopharma stock right now? 5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Kinnate Biopharma in the last year. There are currently 4 hold ratings and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" KNTE shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in KNTE, but not buy additional shares or sell existing shares. View KNTE analyst ratings or view top-rated stocks. What is Kinnate Biopharma's stock price target for 2024? 5 analysts have issued 12 month price targets for Kinnate Biopharma's shares. Their KNTE share price targets range from $4.00 to $26.00. On average, they expect the company's share price to reach $14.60 in the next year. This suggests a possible upside of 557.7% from the stock's current price. View analysts price targets for KNTE or view top-rated stocks among Wall Street analysts. How have KNTE shares performed in 2023? Kinnate Biopharma's stock was trading at $6.10 at the beginning of the year. Since then, KNTE stock has decreased by 63.6% and is now trading at $2.22. View the best growth stocks for 2023 here. When is Kinnate Biopharma's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 20th 2024. View our KNTE earnings forecast. How were Kinnate Biopharma's earnings last quarter? Kinnate Biopharma Inc. (NASDAQ:KNTE) posted its quarterly earnings results on Thursday, November, 9th. The company reported ($0.65) earnings per share for the quarter, beating analysts' consensus estimates of ($0.69) by $0.04. When did Kinnate Biopharma IPO? (KNTE) raised $170 million in an initial public offering (IPO) on Thursday, December 3rd 2020. The company issued 10,000,000 shares at $16.00-$18.00 per share. Goldman Sachs, SVB Leerink, Piper Sandler and Wedbush PacGrow acted as the underwriters for the IPO. Who are Kinnate Biopharma's major shareholders? Kinnate Biopharma's stock is owned by many different institutional and retail investors. Top institutional investors include Lynx1 Capital Management LP (4.24%), Acadian Asset Management LLC (1.56%), Jacobs Levy Equity Management Inc. (0.95%), Citigroup Inc. (0.89%), Citigroup Inc. (0.89%) and Rock Springs Capital Management LP (0.86%). Insiders that own company stock include Carl L Gordon, James B Tananbaum, Orbimed Advisors Llc and Richard Thomas Williams. View institutional ownership trends. How do I buy shares of Kinnate Biopharma? Shares of KNTE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NASDAQ:KNTE) was last updated on 12/11/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kinnate Biopharma Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.